RU2013123275A - PIPERIDIN-4-ILAZETIDINDIAMIDES AS MONOACYLGLYCERINLIPASE INHIBITORS - Google Patents
PIPERIDIN-4-ILAZETIDINDIAMIDES AS MONOACYLGLYCERINLIPASE INHIBITORS Download PDFInfo
- Publication number
- RU2013123275A RU2013123275A RU2013123275/04A RU2013123275A RU2013123275A RU 2013123275 A RU2013123275 A RU 2013123275A RU 2013123275/04 A RU2013123275/04 A RU 2013123275/04A RU 2013123275 A RU2013123275 A RU 2013123275A RU 2013123275 A RU2013123275 A RU 2013123275A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- group
- thiazol
- phenyl
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
1. Соединение формулы (I)формула (I)гдеY и Z независимо выбраны из группы a) или группы b) таким образом, что один из элементов (Y или Z) выбран из группы a), а другой - из группы b);группа a) представляет собойi) C-арил, не имеющий заместителя или замещенный заместителем, выбранным из группы, состоящей из фтора, хлора, C-алкила, C-алкоксила, циано и трифторметила; илиii) не имеющий заместителя гетероарил, выбранный из группы, состоящей из тиазолила, изотиазолила и 1H-пирролила;группа b) представляет собойi) C-арил;ii) гетероарил, выбранный из группы, состоящей из бензоксазолила, бензотиазолила, бензимидазолила, бензотиенила, индазолила и индолила;iii) фенилметилфенил, в котором фенильная группа фенилметила не имеет заместителя или замещена трифторметилом или фтором; илиiv) 1,3-дигидро-3H-бензимидазол-2-онил;в котором представители группы b), отличные от фенилметилфенила, не имеют заместителей или замещены одним или двумя заместителями, независимо выбранными из группы, состоящей из брома, хлора, фтора, йода, C-алкила, C-алкоксила и R; при условии наличия не более одного заместителя R; иRвыбран из группы, состоящей из трифторметила, 2,2,2-трифторэтила, 3,3,3-трифторпропила, 4,4-дифторциклогексила, тиенила, пиридинила и фенила; причем указанные тиенил, пиридинил и фенил в Rне имеют заместителей или замещены одним или двумя заместителями, независимо выбранными из группы, состоящей из трифторметила, метила, хлора, циано и фтора;R представляет собой водород или гидрокси;а также его энантиомеры, диастереомеры, сольваты и фармацевтически приемлемые соли.2. Соединение по п.1, в котором группа a) представляет собой не имеющий заместителя фенил или не имеющий замес�1. The compound of formula (I) formula (I) where Y and Z are independently selected from group a) or group b) such that one of the elements (Y or Z) is selected from group a) and the other from group b); group a) is i) C-aryl not substituted or substituted by a substituent selected from the group consisting of fluoro, chloro, C-alkyl, C-alkoxyl, cyano and trifluoromethyl; or ii) an unsubstituted heteroaryl selected from the group consisting of thiazolyl, isothiazolyl and 1H-pyrrolyl; group b) is i) C-aryl; ii) a heteroaryl selected from the group consisting of benzoxazolyl, benzothiazolyl, benzimidazolyl, benzothienyl, indazolyl and indolyl; iii) phenylmethylphenyl in which the phenyl group of the phenylmethyl has no substituent or is substituted with trifluoromethyl or fluorine; or iv) 1,3-dihydro-3H-benzimidazol-2-onyl; wherein members of group b) other than phenylmethylphenyl have no substituents or are substituted with one or two substituents independently selected from the group consisting of bromine, chlorine, fluorine, iodine, C-alkyl, C-alkoxyl and R; subject to the presence of not more than one substituent R; and R is selected from the group consisting of trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, 4,4-difluorocyclohexyl, thienyl, pyridinyl and phenyl; moreover, these thienyl, pyridinyl and phenyl in R do not have substituents or are substituted by one or two substituents independently selected from the group consisting of trifluoromethyl, methyl, chlorine, cyano and fluorine; R is hydrogen or hydroxy; and also its enantiomers, diastereomers, solvates and pharmaceutically acceptable salts. 2. The compound according to claim 1, in which group a) is non-substituted phenyl or non-substituted�
Claims (16)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40587610P | 2010-10-22 | 2010-10-22 | |
US61/405,876 | 2010-10-22 | ||
PCT/US2011/057085 WO2012054716A1 (en) | 2010-10-22 | 2011-10-20 | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2013123275A true RU2013123275A (en) | 2014-11-27 |
Family
ID=44993878
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2013123275/04A RU2013123275A (en) | 2010-10-22 | 2011-10-20 | PIPERIDIN-4-ILAZETIDINDIAMIDES AS MONOACYLGLYCERINLIPASE INHIBITORS |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP2629851A1 (en) |
JP (1) | JP2013540159A (en) |
KR (1) | KR20130142137A (en) |
CN (1) | CN103260703A (en) |
AR (1) | AR083542A1 (en) |
AU (1) | AU2011316970A1 (en) |
BR (1) | BR112013009858A2 (en) |
CA (1) | CA2815350A1 (en) |
IL (1) | IL225769A0 (en) |
RU (1) | RU2013123275A (en) |
TW (1) | TW201305136A (en) |
WO (1) | WO2012054716A1 (en) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2970121B1 (en) * | 2013-03-15 | 2017-12-13 | Araxes Pharma LLC | Covalent inhibitors of kras g12c |
US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
WO2014143659A1 (en) | 2013-03-15 | 2014-09-18 | Araxes Pharma Llc | Irreversible covalent inhibitors of the gtpase k-ras g12c |
TWI659021B (en) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Inhibitors of kras g12c |
EP3087067B1 (en) | 2013-12-26 | 2018-10-24 | Takeda Pharmaceutical Company Limited | 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors |
JO3556B1 (en) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
WO2016049524A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2016158956A1 (en) | 2015-03-30 | 2016-10-06 | 武田薬品工業株式会社 | Heterocyclic compound |
TW201702232A (en) | 2015-04-10 | 2017-01-16 | 亞瑞克西斯製藥公司 | Substituted quinazoline compounds and methods of use thereof |
US10428064B2 (en) | 2015-04-15 | 2019-10-01 | Araxes Pharma Llc | Fused-tricyclic inhibitors of KRAS and methods of use thereof |
US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
WO2017058768A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
EP3356339A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
WO2017070256A2 (en) | 2015-10-19 | 2017-04-27 | Araxes Pharma Llc | Method for screening inhibitors of ras |
JP7015059B2 (en) | 2015-11-16 | 2022-02-15 | アラクセス ファーマ エルエルシー | 2-substituted quinazoline compounds containing substituted heterocyclic groups and their usage |
WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
US10463753B2 (en) | 2016-02-19 | 2019-11-05 | Lundbeck La Jolla Research Center, Inc. | Radiolabeled monoacylglycerol lipase occupancy probe |
WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
WO2017171100A1 (en) * | 2016-03-31 | 2017-10-05 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
WO2017170830A1 (en) | 2016-03-31 | 2017-10-05 | 武田薬品工業株式会社 | Heterocyclic compound |
US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
EP3519402A1 (en) | 2016-09-29 | 2019-08-07 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
CN110312711A (en) | 2016-10-07 | 2019-10-08 | 亚瑞克西斯制药公司 | Heterocyclic compound and its application method as RAS inhibitor |
US11274093B2 (en) | 2017-01-26 | 2022-03-15 | Araxes Pharma Llc | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
US11059819B2 (en) | 2017-01-26 | 2021-07-13 | Janssen Biotech, Inc. | Fused hetero-hetero bicyclic compounds and methods of use thereof |
EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
WO2018140513A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
CA3063440A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Covalent inhibitors of kras |
US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
WO2018218071A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
CA3076477A1 (en) | 2017-09-29 | 2019-04-04 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
US20200102311A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Pharmaceutica Nv | Monoacylglycerol Lipase Modulators |
CN109879797A (en) * | 2019-01-10 | 2019-06-14 | 安徽昊帆生物有限公司 | N- benzyl-tetrahydropyridines and preparation method thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9812037D0 (en) * | 1998-06-04 | 1998-07-29 | Pfizer Ltd | Piperidones |
US8106208B2 (en) * | 2006-05-18 | 2012-01-31 | Albireo Ab | Benzamide compounds that act as NK receptor antagonists |
FR2915198B1 (en) * | 2007-04-18 | 2009-12-18 | Sanofi Aventis | TRIAZOLOPYRIDINE CARBOXAMIDE AND TRIAZOLOPYRIDINE -CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE. |
EP2283126A1 (en) * | 2008-04-25 | 2011-02-16 | Janssen Pharmaceutica, N.V. | Crystal structure of monoacylglycerol lipase (mgll) |
CN102369186B (en) * | 2009-04-02 | 2014-07-09 | 默克专利有限公司 | Piperidine and piperazine derivatives as autotaxin inhibitors |
RU2011147200A (en) * | 2009-04-22 | 2013-05-27 | Янссен Фармацевтика Нв | ASETIDINYLDIAMIDES AS MONOACYGLYCERINE LIPASE INHIBITORS |
-
2011
- 2011-10-20 CN CN201180061809XA patent/CN103260703A/en active Pending
- 2011-10-20 WO PCT/US2011/057085 patent/WO2012054716A1/en active Application Filing
- 2011-10-20 JP JP2013535086A patent/JP2013540159A/en active Pending
- 2011-10-20 RU RU2013123275/04A patent/RU2013123275A/en not_active Application Discontinuation
- 2011-10-20 AU AU2011316970A patent/AU2011316970A1/en not_active Abandoned
- 2011-10-20 EP EP11784828.3A patent/EP2629851A1/en not_active Withdrawn
- 2011-10-20 KR KR1020137012911A patent/KR20130142137A/en not_active Application Discontinuation
- 2011-10-20 CA CA2815350A patent/CA2815350A1/en not_active Abandoned
- 2011-10-20 BR BR112013009858A patent/BR112013009858A2/en not_active IP Right Cessation
- 2011-10-21 TW TW100138198A patent/TW201305136A/en unknown
- 2011-10-24 AR ARP110103927A patent/AR083542A1/en not_active Application Discontinuation
-
2013
- 2013-04-15 IL IL225769A patent/IL225769A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112013009858A2 (en) | 2016-07-26 |
AR083542A1 (en) | 2013-03-06 |
IL225769A0 (en) | 2013-06-27 |
AU2011316970A1 (en) | 2013-05-09 |
CN103260703A (en) | 2013-08-21 |
JP2013540159A (en) | 2013-10-31 |
EP2629851A1 (en) | 2013-08-28 |
TW201305136A (en) | 2013-02-01 |
CA2815350A1 (en) | 2012-04-26 |
KR20130142137A (en) | 2013-12-27 |
WO2012054716A1 (en) | 2012-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2013123275A (en) | PIPERIDIN-4-ILAZETIDINDIAMIDES AS MONOACYLGLYCERINLIPASE INHIBITORS | |
RU2013114771A (en) | AZETIDINYL DIAMIDS AS INHIBITORS OF MONOACYL GLYCEROL OF LIPASE | |
RU2013114852A (en) | OXOPIPERAZINE-AZETIN AMIDES AND OXODIAZEPIN-AZETIDINE AMIDES AS LIPASE MONACYLGLYCEROL INHIBITORS | |
RU2011147181A (en) | ASETIDINYLDIAMIDES AS MONOACYGLYCERINE LIPASE INHIBITORS | |
ES2557281T3 (en) | Amide compounds, compositions and uses thereof | |
AU2014233414B2 (en) | N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
PE20110063A1 (en) | DERIVATIVES OF [1, 2, 4] TRIAZOLO [1, 5-a] PYRIDINE AS JAK INHIBITORS | |
AU2018360850A1 (en) | Modulators of the integrated stress pathway | |
JP6632532B2 (en) | Pyrimidinone derivatives having autotaxin inhibitory activity | |
TN2014000033A1 (en) | INDAZOLES | |
AR089134A1 (en) | ARILOS AND INHIBITING BICYCLE HETEROARILS OF THE SODIUM CHANNELS | |
JP2010534647A5 (en) | ||
RU2010106854A (en) | 2-AZA-Bicyclo derivatives [3.3.0] | |
JP2016515562A5 (en) | ||
CA2522024A1 (en) | Cgrp receptor antagonists | |
RU2015123499A (en) | COMPOUNDS OF SUBSTITUTED TRIAZOLBORONIC ACID | |
JP2020507582A5 (en) | ||
WO2015143654A1 (en) | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF | |
EA200901573A1 (en) | Heteroaryl Thiazole Substituents | |
RU2018120242A (en) | QUINOLINE COMPOUNDS, METHODS FOR PRODUCING AND USING THEM AS A MEDICINAL INHIBITING THE URATE TRANSPORT | |
CA2403423A1 (en) | Tri-aryl-substituted-ethane pde4 inhibitors | |
RU2010102990A (en) | Oxadiazole derivatives as DGAT inhibitors | |
CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
JP6967000B2 (en) | Cephem compounds, their production and use | |
JP2016503403A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160217 |